Portal de Periódicos da CAPES

The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations

2022; Springer Nature; Volume: 127; Issue: 1 Linguagem: Inglês

10.1038/s41416-022-01770-1

1532-1827

Joanna Tomiczek‐Szwiec, Marek Szwiec, Michał Falco, Cezary Cybulski, Dominika Wokołorczyk, Anna Jakubowska, Jacek Gronwald, Małgorzata Stawicka, Dariusz Godlewski, Ewa Kilar, Elżbieta Marczyk, Monika Siołek, Rafał Wiśniowski, Olga Haus, Robert Sibilski, Lubomir Bodnar, Ping Sun, Steven A. Narod, Jan Lubiński, Tomasz Huzarski, Maria Błasińska-Morawiec, Maria Chosia, Kazimierz Drosik, S. Gozdecka-Grodecka, Stanisław Góźdż, Ewa Grzybowska, Arkadiusz Jeziorski, Aldona Karczewska, Radzisław Kordek, Agnieszka Synowiec, Beata Kozak‐Klonowska, Katarzyna Lamperska, Dariusz Lange, Andrzej Maćkiewicz, Jerzy Mituś, Stanisław Niepsuj, Oleg Oszurek, K Gugała, Zbigniew Morawiec, Tomasz Mierzwa, Michał Posmyk, Janusz Ryś, Cezary Szczylik, Michał Uciński, Krzysztof Urbański, Bernard Waśko, Piotr Wandzel,

Male Breast Health Studies

To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation.Women with Stage I-III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation. Control patients without a CHEK2 mutation were selected from a database of patients treated over the same time period. Information on treatments received and distant recurrences were retrieved from medical records. Treatments included chemotherapy, hormonal therapy (tamoxifen) and radiation therapy. Oophorectomies were performed for the treatment of breast cancer or for benign conditions. Dates of death were obtained from the Polish Vital Statistics Registry. Causes of death were determined by medical record review. Predictors of survival were determined using the Cox proportional hazards model.In all, 839 patients with a CHEK2 mutation were matched to 839 patients without a mutation. The mean follow-up was 12.0 years. The 15-year survival for CHEK2 carriers was 76.6% and the 15-year survival for non-carrier control patients was 78.8% (adjusted HR = 1.06; 95% CI: 0.84-1.34; P = 0.61). Among CHEK2 carriers, the 15-year survival for women who had an oophorectomy was 86.3% and for women who did not have an oophorectomy was 72.1% (adjusted HR = 0.59; 95% CI: 0.38-0.90; P = 0.02). Among controls, the 15-year survival for patients who had an oophorectomy was 84.5% and for women who did not have an oophorectomy was 77.6% (adjusted HR = 1.03; 95% CI: 0.66-1.61; P = 0.90).Among women with breast cancer and a CHEK2 mutation, oophorectomy is associated with a reduced risk of death from breast cancer.